This multicentre, national study examined the impact of COVID-19 disease on patients with cancer from March 2020 to April 2022.

Results indicated that patients with blood cancers tested positive for COVID-19 on PCR for a considerably longer time than those with solid organ tumours. Chemotherapy type or specific immunosuppressive therapies were not predictive of severe disease.

Reassuringly, the severity of COVID-19 disease in patients with cancer has decreased over time. This coincides with increasing rates of vaccination, hybrid immunity, robust testing mechanisms and the availability of and early use of antiviral therapies.  

Even though newer strains of COVID-19 have the potential for evading protection induced by vaccination and antibody therapies, there is still good cross protection due to T-cell immunity. Therefore, a 3-dose course of primary vaccination as well as booster doses is recommended for severely immunocompromised individuals.  

Medical Journal of Australia: Local research examines COVID’s impact on cancer patients